VolitionRx Partners with Hologic to Expand Access to Nu.Q® Discover Epigenetic Profiling Service
TL;DR
VolitionRx gains market advantage through its co-marketing agreement with Hologic, expanding access to its $200 million annual market Nu.Q Discover assays.
VolitionRx's agreement with Hologic provides drug developers with epigenetic profiling assays across disease model development, preclinical testing, and clinical studies.
This partnership advances epigenetic research to help detect diseases earlier, potentially improving patient outcomes and quality of life through better diagnostics.
VolitionRx collaborates with Hologic to offer nucleosome quantification services, providing novel biological insights across oncology and neurodegenerative diseases.
Found this article helpful?
Share it with your network and spread the knowledge!
VolitionRx Ltd. has entered into a co-marketing and services agreement with Hologic Diagenode, part of Hologic Inc., to promote Volition's Nu.Q® Discover service. This partnership represents a strategic move to expand customer access to Volition's proprietary epigenetic profiling assays across multiple disease areas. The program offers drug developers and scientists a comprehensive suite of assays for rapid epigenetic profiling throughout disease model development, preclinical testing, and clinical studies.
Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition, described the agreement as a significant milestone for the Nu.Q® Discover program. The partnership is expected to greatly expand customer access to Volition's proprietary assays, which target an estimated total addressable market of $200 million annually. This collaboration strengthens Volition's position in the growing pharmaco-epigenetics market while supporting revenue growth through expanded service offerings.
Raphael Werding, Head of Life Sciences at Hologic, expressed enthusiasm for adding Nu.Q® Discover to Hologic's service portfolio. Hologic brings extensive experience in oncology and other disease areas including cardiovascular, neurodegenerative, and immunology research. The company believes nucleosome quantification can provide valuable biological insights to its diverse client base of biotech companies, pharmaceutical firms, and academic institutions.
The agreement establishes Hologic as a co-marketing partner for Nu.Q® Discover with its established customer base for an initial one-year term. The partnership includes potential for expansion into an exclusive provider arrangement subject to further terms and performance metrics. This strategic alliance leverages Hologic's established market presence and Volition's epigenetic technology expertise to create synergies in the life sciences research market.
For more information about Volition's epigenetic research and development activities, visit https://www.Volition.com. The company maintains research and development operations in Belgium, with additional innovation facilities in the United States and London. This international presence supports Volition's mission to advance epigenetic science across global markets.
The partnership between Volition and Hologic represents a significant development in the pharmaco-epigenetics landscape, combining Volition's specialized epigenetic profiling capabilities with Hologic's broad market reach and expertise across multiple disease areas. This collaboration has the potential to accelerate drug development processes by providing researchers with advanced epigenetic analysis tools throughout the research and development pipeline.
Curated from InvestorBrandNetwork (IBN)
